I agree with your post. They won't lose Health Net if they settled. That's a victory and really all Amarin was looking for from the start. The judge's ruling keeping Health Net in the case was all Amarin needed to get a settlement. There's no way an insurance company would let this go to trial and risk setting a precedent it would have to follow with 1,000 other drugs.
Meanwhile, I've started to wonder if Amarin is hoping that its settlement with Health Net will enable it to continue the deals it has made with other carriers to secure 60 percent of the market. It likely will make those carriers who agreed to deals with Amarin more likely to continue them. And, I'm sure the company hopes it might convince a few others to join the deal. Ultimately, if the market for Vascepa doubles as a result of a great outcome in the COVID trial or the Alzheimer's trial, Amarin could turn a nice profit in the United States while also covering all of its fixed costs so that Europe and everywhere else would be gravy for profits.
If there's one thing that has worked well in the last year, it's the deals Amarin made to secure 60 percent of the market. Kind of interesting because there was no talk of them until they were all completed. So we never really know what's going on behind the scenes. We probably know 30 percent of what's really going on and then everybody on this board speaks pompously about what the company should or shouldn't do and how great Denner would be and blah, blah, blah when we're really all in the dark.
News 
Market Data 
Discover 
